MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$1,601,491
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Sale of marketable securities
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Change in fair value of warrant ...
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-2,154,405
-3,207,636
-3,038,277
-7,996,062
Depreciation and amortization
52,394
52,836
52,620
104,529
Dividend and interest income
6,064
34,695
59,336
176,542
Stock-based compensation
290,215
447,860
399,932
2,477,834
Change in fair value of warrant liabilities
1,220,121
568,966
612,064
-59,528
Accounts receivable
-2,200
2,100
-1,600
-173,400
Prepaid expenses and other current assets
25,938
-82,777
2,366
-21,359
Lease liability
-
-
-
0
Non-cash lease expense
-
-
-
0
Deferred revenue
-
-
-
0
Accounts payable
-682,003
482,455
230,209
126,861
Gain on exchange of warrants
-
-
-
0
Accrued expenses and other current liabilities
-64,070
332,296
126,545
-263,560
Net cash used in operating activities
-3,807,792
-2,415,173
-2,901,137
-5,472,653
Sale of marketable securities
1,043,367
2,480,343
2,548,105
6,664,238
Purchases of equipment
-
79,669
0
36,400
Purchase of marketable securities
74,920
0
550,467
2,128,680
Net cash provided by investing activities
968,447
2,400,674
1,997,638
4,499,158
Exercise of stock options
-
-1,246
0
42,411
Proceeds from issuance of common stock for cash
-
1,085,000
0
2,011,250
Proceeds from issuance of common stock and pre-funded warrants in registered direct offering
5,000,000
-
-
-
Payment of issuance costs
559,164
105,148
0
72,805
Proceeds from exchange and issuance of warrants, net
-
-
-
0
Payment of deferred offering costs
-
50,665
49,308
0
Repayment of financed insurance premiums
-
4,698
-
-
Net cash provided by financing activities
4,440,836
923,243
-49,308
1,980,856
Net increase in cash and cash equivalents
1,601,491
908,744
-952,807
1,007,361
Cash and cash equivalents - beginning of the period
1,511,188
602,444
547,890
-
Cash and cash equivalents - end of the period
3,112,679
1,511,188
602,444
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$5,000,000
Sale of marketable
securities
$1,043,367
Net cash provided by
financing activities
$4,440,836
Net cash provided by
investing activities
$968,447
Canceled cashflow
$559,164
Canceled cashflow
$74,920
Net increase in cash
and cash...
$1,601,491
Canceled cashflow
$3,807,792
Payment of issuance
costs
$559,164
Stock-based compensation
$290,215
Depreciation and
amortization
$52,394
Accounts receivable
-$2,200
Purchase of marketable
securities
$74,920
Net cash used in
operating activities
-$3,807,792
Canceled cashflow
$344,809
Net loss
-$2,154,405
Change in fair value of
warrant liabilities
$1,220,121
Accounts payable
-$682,003
Accrued expenses and
other current...
-$64,070
Prepaid expenses and
other current assets
$25,938
Dividend and interest
income
$6,064
Buy us a coffee
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)